# Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx

> **NCT01187953** · PHASE3 · COMPLETED · sponsor: **Veloxis Pharmaceuticals** · enrollment: 543 (actual)

## Conditions studied

- Renal Failure

## Interventions

- **DRUG:** Prograf (tacrolimus)
- **DRUG:** LCP-Tacro

## Key facts

- **NCT ID:** NCT01187953
- **Lead sponsor:** Veloxis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-03
- **Final completion:** 2014-03
- **Target enrollment:** 543 (ACTUAL)
- **Last updated:** 2016-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01187953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01187953, "Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01187953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*